Search hospitals
>
Texas
>
Houston
Texas Children's Hospital
Claim this profile
Houston, Texas 77030
Global Leader in Brain Tumor
Global Leader in Cancer
Conducts research for HIV Infection
Conducts research for Leukemia
Conducts research for Mixed-Cell Lymphoma
782 reported clinical trials
118 medical researchers
Summary
Texas Children's Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Brain Tumor, Cancer, HIV Infection, Leukemia, Mixed-Cell Lymphoma and other specialties. Texas Children's Hospital is involved with conducting 782 clinical trials across 1,168 conditions. There are 118 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Carlos Ramos, MD, and Rayne H. Rouce.
Area of expertise
Brain Tumor
Texas Children's Hospital has run 50 trials for Brain Tumor. Some of their research focus areas include:
Cancer
Texas Children's Hospital has run 40 trials for Cancer. Some of their research focus areas include:
Top PIs
Jennifer Foster, MD
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
3 years of reported clinical research
Patricia Baxter, MD
Texas Children's Hospital
3 years of reported clinical research
Carlos Ramos, MD
Houston Methodist Hospital
3 years of reported clinical research
Rayne H. Rouce
Texas Children's Hospital
6 years of reported clinical research
Clinical Trials running at Texas Children's Hospital
Cancer
Crohn's Disease
Brain Tumor
Adrenoleukodystrophy
Inflammatory Bowel Disease
Cystic Fibrosis
Type 2 Diabetes
Leukoencephalopathy
Genetic Disorders
Craniopharyngioma
Onivyde + Talazoparib/Temozolomide
for Ewing Sarcoma
The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm. In Arm A, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and talazoparib. Onivyde works by damaging the DNA of the cancer cell and talazoparib works by blocking the repair of the DNA once the cancer cell is damaged. By damaging the tumor DNA and blocking the repair, the cancer cells may die. In Arm B, children and AYAs with recurrent or refractory solid tumors will receive 2 medications called Onivyde and temozolomide. Both of these medications work by damaging the DNA of the cancer call which may cause the tumor(s) to die. Once the highest doses are reached in Arm A and Arm B, then "expansion Arms" will open. An expansion arm treats more children and AYAs with recurrent or refractory solid tumors at the highest doses achieved in the phase I study. The goal of the expansion arms is to see if the tumors go away in children and AYAs with recurrent or refractory solid tumors. There will be 3 "expansion Arms". In Arm A1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and talazoparib. In Arm A2, children and AYAs with recurrent or refractory solid tumors, whose tumors have a problem with repairing DNA (identified by their doctor), will receive Onivyde and talazoparib. In Arm B1, children and AYAs with recurrent or refractory solid tumors (excluding Ewing sarcoma) will receive Onivyde and temozolomide. Once the highest doses of medications used in Arm A and Arm B are determined, then a phase II study will open for children or young adults with Ewing sarcoma that has recurred or is refractory following treatment received after the initial diagnosis. The trial will test the same 2 combinations of therapy in Arm A and Arm B. In the phase II, a participant with Ewing sarcoma will be randomly assigned to receive the treatment given on either Arm A or Arm B.
Recruiting
1 award
Phase 1 & 2
14 criteria
Tagraxofusp
for Blood Cancers
Tagraxofusp is a protein-drug conjugate consisting of a diphtheria toxin redirected to target CD123 has been approved for treatment in pediatric and adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). This trial aims to examine the safety of this novel agent in pediatric patients with relapsed/refractory hematologic malignancies. The mechanism by which tagraxofusp kills cells is distinct from that of conventional chemotherapy. Tagraxofusp directly targets CD123 that is present on tumor cells, but is expressed at lower or levels or absent on normal hematopoietic stem cells. Tagraxofusp also utilizes a payload that is not cell cycle dependent, making it effective against both highly proliferative tumor cells and also quiescent tumor cells. The rationale for clinical development of tagraxofusp for pediatric patients with hematologic malignancies is based on the ubiquitous and high expression of CD123 on many of these diseases, as well as the highly potent preclinical activity and robust clinical responsiveness in adults observed to date. This trial includes two parts: a monotherapy phase and a combination chemotherapy phase. This design will provide further monotherapy safety data and confirm the FDA approved pediatric dose, as well as provide safety data when combined with chemotherapy. The goal of this study is to improve survival rates in children and young adults with relapsed hematological malignancies, determine the recommended phase 2 dose (RP2D) of tagraxofusp given alone and in combination with chemotherapy, as well as to describe the toxicities, pharmacokinetics, and pharmacodynamic properties of tagraxofusp in pediatric patients. About 54 children and young adults will participate in this study. Patients with Down syndrome will be included in part 1 of the study.
Recruiting
1 award
Phase 1
Long-Term Effects Study
for Childhood Cancer Survivors
The Childhood Cancer Survivor Study (CCSS) will investigate the long-term effects of cancer and its associated therapies. A retrospective cohort study will be conducted through a multi-institutional collaboration, which will involve the identification and active follow-up of a cohort of approximately 50,000 survivors of cancer, diagnosed before 21 years of age, between 1970 and 1999 and 10,000 sibling controls. This project will study children and young adults exposed to specific therapeutic modalities, including radiation, chemotherapy, and/or surgery, who are at increased risk of late-occurring adverse health outcomes. A group of sibling controls will be identified and data collected for comparison purposes.
Recruiting
1 award
N/A
3 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Texas Children's Hospital?
Texas Children's Hospital is a medical facility located in Houston, Texas. This center is recognized for care of Brain Tumor, Cancer, HIV Infection, Leukemia, Mixed-Cell Lymphoma and other specialties. Texas Children's Hospital is involved with conducting 782 clinical trials across 1,168 conditions. There are 118 research doctors associated with this hospital, such as Jennifer Foster, MD, Patricia Baxter, MD, Carlos Ramos, MD, and Rayne H. Rouce.
Where is Texas Children's Hospital located?
**Directions to Texas Children's Hospital, Houston:** - For direct access, take I-69 to Fannin St and proceed south. - For real-time navigation, use the Waze app and enter the address: 6621 Fannin St.
Who should I call to ask about financial aid or insurance network?
### Texas Children's Hospital Contact Information **Financial Assistance and Insurance Departments:** - **Hospital Billing Office:** 832-824-2300 - **Texas Children's Health Plan Member Services:** - **CHIP:** 832-828-1002 (Local), 1-866-959-6555 (Toll-Free), TTY 800-735-2989 - **STAR:** 832-828-1001 (Local), 1-866-959-2555 (Toll-Free), TTY 800-735-2989 - **STAR Kids:** 832-828-1003 (Local), 1-800-659-5764 (Toll-Free), TTY 800-735-2989 **Appeals Department:** - **Address:** Texas Children’s Health Plan Attention: Appeals Department NB8390, PO Box 300709, Houston, TX 77230 - **Fax:** 832-825-8796 - **Phone:** 832-828-1001 or 1-866-959-2555, TTY/TDD: 1-800-735-2989 ### UT Southwestern Medical Center Contact Information **Financial Assistance:** - **Phone:** 469-291-2000 or 866-648-2455 - **Address:** Financial Assistance, P.O. Box 36423, Dallas, Texas 75235-9662
What insurance does Texas Children's Hospital accept?
Texas Children's Hospital accepts a wide range of insurance plans, including but not limited to Aetna HMO, Aetna POS, Aetna PPO, BCBS BlueChoice PPO/EPO, BCBS Blue Essentials, BCBS Par Plan, and Choice Care Network PPO (Humana). Additionally, Texas Children's Health Plan provides no-cost health coverage for eligible children and young adults under 21 with disabilities. For the most current information on accepted insurance plans, contacting the hospital directly is advised.
What awards or recognition has Texas Children's Hospital received?
Texas Children's Hospital in Houston, Texas, is renowned for its pediatric cancer care, ranking among the nation's best by U.S. News & World Report. It boasts over 250 active therapeutic clinical trials and receives $40 million in annual research funding. The Jan and Dan Duncan Neurological Research Institute focuses on pediatric and adult brain disorders, with over 25 principal investigators and 200 scientists.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.